Novo has signed a research collaboration with fellow Danish company Orbis Medicines to discover multiple macrocyclic peptides aimed at unnamed cardiometabolic targets, a deal under which Orbis could receive as much as $1.4 billion in upfront and downstream payments plus sales royalties, Orbis said Thursday. The partnership is a bet on oral macrocyclic peptides — ring-shaped molecules that may be able to replace injectable biologic medicines — and marks a further step in Novo’s push into oral biologics as it rebuilds after losing leadership in obesity and diabetes to Eli Lilly.
For the peptide therapy and research peptide industry, the deal matters less for its headline number than for what it signals about where large pharmaceutical capital is flowing. If macrocycles can deliver oral bioavailability for molecules that today require subcutaneous injection, the competitive ground shifts for injectable GLP-1 products, for the injection pen and vial supply chain built around them, and for the contract manufacturers and API suppliers that serve the peptide sector.
What Novo and Orbis actually agreed to
According to Orbis, the two companies will pursue the discovery of multiple macrocycles that the company describes as having the “potential to replace injectable medicines.” The companies did not specify how many drugs the collaboration covers, nor which diseases it targets; they said only that the work will address unnamed cardiometabolic targets.
The financial terms are structured as potential consideration rather than a committed sum: Orbis could receive as much as $1.4 billion in upfront and downstream payouts, as well as sales royalties. That figure represents the maximum potential value of the deal, not an amount already paid, and no milestone schedule or payment timing was disclosed.
Orbis is a Danish biotech that launched with $93 million in January 2025. The company says it uses a platform it calls “nGen” to model and design molecules that are “both orally bioavailable and capable of modulating challenging intra- and extracellular targets.” That description is a company claim and has not been independently verified in the reporting.
The absorption problem macrocycles are meant to solve
The strategic logic behind the deal is easiest to see in Novo’s own oral formulation. The highest dose of Novo’s Wegovy pill contains 20 times the highest injectable dose, because most of the drug’s active ingredient is broken down before it reaches the bloodstream. That gap illustrates why oral peptide delivery has been so difficult: the gastrointestinal tract degrades and poorly absorbs the molecules that work well when injected.
Macrocycles are one route around that constraint. Their ring structure can improve stability and permeability relative to linear peptides, which is why the class has attracted attention as a way to combine biologic-like specificity with pill-based administration. Industry observers note that the use of macrocycles is one way Novo could overcome some of the limitations of standard oral peptide medicines, such as poor digestive absorption — an analytical reading of the deal’s rationale rather than a stated company objective.
Biologic drugs such as peptides and antibodies are primarily delivered through infusions or injections, with subcutaneous “pens” being the most patient-friendly options. Drugmakers have long searched for ways to pack a biologic into a pill, hoping to help further improve convenience and medication adherence. The commercial stakes are significant: an oral version of a chronic-use metabolic drug removes cold-chain handling, needle logistics and much of the training burden that currently sits with clinics and telehealth operators.
Key figures in the Novo–Orbis agreement
| Item | Detail | Status |
|---|---|---|
| Maximum potential payout to Orbis | Up to $1.4 billion in upfront and downstream payments, plus sales royalties | Reported; maximum potential value, not a paid amount |
| Targets | Unnamed cardiometabolic targets | Reported; number of drugs and diseases not disclosed |
| Wegovy oral pill dose vs. injectable | Highest pill dose is 20 times the highest injectable dose | Reported; attributed to breakdown of active ingredient before reaching the bloodstream |
| Orbis launch funding | $93 million, January 2025 | Reported |
| Orbis discovery platform | “nGen,” used to model and design orally bioavailable molecules | Company claim; not independently verified |
Why the macrocycle class is drawing pharma capital
The Novo–Orbis agreement is not an isolated transaction. Merck & Co. brought such a treatment to market earlier this year when it won approval of the cholesterol-lowering medication Lipfendra, giving the macrocyclic peptide class a regulatory precedent. A group of startups are working on other ways to advance the technology, among them Orbis, Unnatural Products and Dayra Therapeutics; all three have now signed deals with larger drugmakers.
That pattern — three early-stage platform companies each paired with an established pharmaceutical partner — suggests large companies are buying optionality on oral biologic delivery rather than committing to a single validated mechanism. The evidence base remains thin at the platform level: a single approved macrocyclic peptide in an unrelated therapeutic area does not establish that the same chemistry will work for cardiometabolic targets, and no clinical data or development timeline for the Novo–Orbis programs has been disclosed.
For suppliers and manufacturers, the read-across is directional rather than immediate. Macrocyclic peptides still require peptide synthesis, purification and analytical control, so demand for solid-phase and hybrid synthesis capacity would not disappear in an oral future. What could change is the downstream format: fewer vials, cartridges and injection pens, and more tablet formulation, excipient compatibility and oral solid-dosage capacity. 多肽供应链资源网 as a provider in the industry domain tracks these shifts across API sourcing, fill-finish and packaging categories.
Novo’s wider reset frames the deal
Novo is in the midst of a reboot that follows its loss of leadership in obesity and diabetes medicines to Eli Lilly. Over the last year or so, the company has swapped CEOs, laid off staff and reshuffled its board. Earlier this week, the company also announced a corporate rebranding that will see it drop “Nordisk” from its name in day-to-day use. It has invested heavily in AI tools, too, most recently through an alliance with Anthropic.
Seen against that backdrop, the Orbis collaboration fits two themes in Novo’s current strategy: external research partnerships to refill the pipeline, and AI-enabled drug design. Orbis’s nGen platform is presented as an AI-driven modeling and design engine, which aligns with Novo’s stated interest in computational tools. The available evidence does not establish that AI capability was the primary reason for the deal, and the companies have not described how the platform will be applied to specific targets.
Nor does the reporting establish a direct causal link between Novo’s restructuring and this specific agreement. The two facts sit side by side: a company under competitive pressure, and a company signing an early-stage oral peptide deal. Treating the second as a consequence of the first is an inference, not a reported fact.
What this means for peptide clinics, telehealth and supply chains
For operators of peptide therapy clinics and telehealth platforms, oral macrocyclic peptides remain a medium-term consideration rather than a near-term procurement change. No approved oral macrocyclic GLP-1 product exists, and the Novo–Orbis programs have no disclosed clinical stage. Any future product in this class would still require prescription and medical supervision, and would be subject to the same regulatory pathways as other prescription medicines.
For buyers and research suppliers, the more practical lesson concerns evidence discipline. A platform claim about oral bioavailability is not the same as demonstrated human bioavailability; a single approved drug in another indication is not proof that a class works across targets. The same distinction applies to research peptides, which are supplied for laboratory use and are not approved treatments. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Clinic-side procurement questions are likely to focus on continuity of injectable supply while oral alternatives mature, and on documentation standards for any peptide product a clinic handles. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
What to watch next
- Disclosure of targets and molecule count. The agreement names no diseases and no number of programs; any future specificity would clarify whether this is a broad platform bet or a narrow asset deal.
- Clinical progression. No timeline or investigational stage has been reported. Preclinical or platform data would not establish human efficacy.
- Payment structure. The $1.4 billion is a maximum potential figure; the split between upfront, milestones and royalties is undisclosed.
- Peer deals. Orbis, Unnatural Products and Dayra Therapeutics have each signed with larger drugmakers, so comparable terms may emerge as a benchmark for oral peptide platform valuations.
- Manufacturing format shift. Any move toward oral macrocyclic peptides would gradually change demand across vials, dual-chamber cartridges and injection pens — a shift worth monitoring through peptidescm supply-chain reporting.
Frequently asked questions
What did Novo and Orbis Medicines agree to?
They signed a research collaboration to discover multiple macrocyclic peptides directed at unnamed cardiometabolic targets, with Orbis eligible for up to $1.4 billion in upfront and downstream payments plus sales royalties.
Are oral macrocyclic peptides approved for obesity or diabetes?
No. The only approved macrocyclic peptide cited in the reporting is Merck & Co.’s cholesterol-lowering Lipfendra. The Novo–Orbis programs have no disclosed clinical stage, and no oral macrocyclic GLP-1 product is approved.
Why does Novo need macrocycles if it already sells an oral Wegovy pill?
Because oral peptide absorption is inefficient. The highest dose of Novo’s Wegovy pill contains 20 times the highest injectable dose, since most of the active ingredient is broken down before reaching the bloodstream.
Does this deal change anything for peptide clinics right now?
Not directly. Injectable GLP-1 products and their pen, vial and cartridge supply chains remain the operating reality; oral macrocyclic peptides would require approval, prescription and medical supervision before any clinical use.
Comments